Immunotherapy for patients with acute psychosis and serum N-Methyl d-Aspartate receptor (NMDAR) antibodies: A description of a treated case series

Schizophrenia Research

Volumn 160, Issue 1-3, 2014, Pages 193-195

  Zandi, Michael S ^a,b   Deakin, Julia B ^a,b   Morris, Katrina ^c   Buckley, Camilla ^c   Jacobson, Leslie ^c   Scoriels, Linda ^a,e   Cox, Amanda L ^a,b   Coles, Alasdair J ^a,b   Jones, Peter B ^a,b   Vincent, Angela ^c   Lennox, Belinda R ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NIHR Cambridge Biomedical Research Centre   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RITUXIMAB; AUTOANTIBODY; IMMUNOGLOBULIN G; NEUROLEPTIC AGENT;

ACUTE PSYCHOSIS; ANTIBODY BLOOD LEVEL; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; FEMALE; FUNCTIONAL STATUS; HUMAN; IMMUNOTHERAPY; LETTER; PLASMAPHERESIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RADIOIMMUNOPRECIPITATION; RANKIN SCALE; SCORING SYSTEM; SYMPTOM; TREATMENT RESPONSE; ACUTE DISEASE; BLOOD; IMMUNOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 84928233465     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.11.001     Document Type: Letter

References (16)

1. Brenner T., Sills G.J., Hart Y., Howell S., Waters P., Brodie M.J., Vincent A., Lang B. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 2013, 54(6):1028-1035.
2. Brown J.W., Martin P.J., Thorpe J.W., Michell A.W., Coles A.J., Cox A.L., Vincent A., Zandi M.S. Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. J. Neuroimmunol. 2014, 271(1-2):66-68.
3. Dalmau J., Tuzun E., Wu H.Y., Masjuan J., Rossi J.E., Voloschin A., Baehring J.M., Shimazaki H., Koide R., King D., Mason W., Sansing L.H., Dichter M.A., Rosenfeld M.R., Lynch D.R. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 2007, 61(1):25-36.
4. Hacohen Y., Dlamini N., Hedderly T., Hughes E., Woods M., Vincent A., Lim M. N-methyl-D-aspartate receptor antibody-associated movement disorder without encephalopathy. Dev. Med. Child Neurol. 2014, 56(2):190-193.
5. Irani S.R., Bera K., Waters P., Zuliani L., Maxwell S., Zandi M.S., Friese M.A., Galea I., Kullmann D.M., Beeson D., Lang B., Bien C.G., Vincent A. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133(Pt 6):1655-1667.
6. Kahn R.S., Sommer I.E. The neurobiology and treatment of first-episode schizophrenia. Mol. Psychiatry 2014, 10.1038/mp.2014.66.
7. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
8. Kayser M.S., Titulaer M.J., Gresa-Arribas N., Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013, 70(9):1133-1139.
9. McGorry P.D., Edwards J., Mihalopoulos C., Harrigan S.M., Jackson H.J. EPPIC: an evolving system of early detection and optimal management. Schizophr. Bull. 1996, 22(2):305-326.
10. NICE National Institute for Clinical Excellence 2009, (Leicester (UK)).
11. Pollak T.A., McCormack R., Peakman M., Nicholson T.R., David A.S. Prevalence of anti-N-methyl-d-aspartate (NMDA) antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol. Med. 2013, 1-13.
12. Titulaer M.J., McCracken L., Gabilondo I., Armangue T., Glaser C., Iizuka T., Honig L.S., Benseler S.M., Kawachi I., Martinez-Hernandez E., Aguilar E., Gresa-Arribas N., Ryan-Florance N., Torrents A., Saiz A., Rosenfeld M.R., Balice-Gordon R., Graus F., Dalmau J. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013, 12(2):157-165.
13. Vincent A., Buckley C., Schott J.M., Baker I., Dewar B.K., Detert N., Clover L., Parkinson A., Bien C.G., Omer S., Lang B., Rossor M.N., Palace J. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004, 127(Pt 3):701-712.
14. Zandi M.S., Irani S.R., Lang B., Waters P., Jones P.B., McKenna P., Coles A.J., Vincent A., Lennox B.R. Disease-relevant autoantibodies in first episode schizophrenia. J. Neurol. 2011, 258(4):686-688.
15. Zandi M.S., Paterson R.W., Ellul M.A., Jacobson L., Al-Diwani A., Jones J.L., Cox A.L., Lennox B., Stamelou M., Bhatia K.P., Schott J.M., Coles A.J., Kullmann D.M., Vincent A. Clinical relevance of serum antibodies to extracellular N-methyl-d-aspartate receptor epitopes. J. Neurol. Neurosurg. Psychiatry 2014, 10.1136/jnnp-2014-3.
16. Zuliani L., Graus F., Giometto B., Bien C., Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J. Neurol. Neurosurg. Psychiatry 2012, 83(6):638-645.